This page is dedicated to keeping you up to date on the latest SCN2A news and studies. Here you will be able to explore the latest articles, contribute to community posts, read other people’s stories, and much more.
Praxis Precision Medicines Partners With Ciitizen To Improve Patient-Guided Drug Development
Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEERead More >
Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations For Severe Pediatric Epilepsy Programs
FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEERead More >